# Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits

> **NCT03616496** · NA · COMPLETED · sponsor: **Central Hospital, Nancy, France** · enrollment: 67 (actual)

## Conditions studied

- Cardiac Amyloidosis

## Interventions

- **DRUG:** Neuraceq PET/CT imaging

## Key facts

- **NCT ID:** NCT03616496
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-06
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-02-10
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616496, "Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03616496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*